세계의 항체 치료제 시장 - 시장 규모, 점유율, 동향 분석 보고서 : 투여 경로별, 포맷별, 유래별, 최종 사용자별, 질환 영역별, 지역별 전망 및 예측(2023-2030년)

The Global Antibody Therapeutics Market size is expected to reach $631.3 billion by 2030, rising at a market growth of 14.4% CAGR during the forecast period.

Antibody therapeutics are explored to prevent and treat respiratory infections, like those caused by respiratory syncytial virus (RSV), influenza, and other respiratory pathogens. Thus, the Infectious Diseases segment acquired $27,652.5 million in 2022. Monoclonal antibodies can provide passive immunity and reduce the risk of severe disease. It offers a form of passive immunization, providing immediate protection against infectious agents. This is particularly important in situations where there is a need for rapid intervention, such as in the case of post-exposure prophylaxis. Some of the factors impacting the market are technological advancements in antibody engineering, increasing number of senior citizens and high development costs of antibody therapeutics.

Advances in antibody engineering technologies, including antibody-drug conjugates (ADCs), Fc engineering, and next-generation sequencing, enhance the properties and performance of antibody therapeutics. These technological advancements contribute to developing more potent, specific, and well-tolerated antibody drugs. Single-cell antibody technologies enable the isolation and characterization of individual B cells, allowing for the identification of rare and high-affinity antibodies. This approach is particularly valuable when traditional hybridoma or phage display methods may not capture the full diversity of the immune response. Single-cell antibody technologies contribute to developing antibodies with enhanced specificity and functionality. Additionally, the aging process is associated with an elevated risk of various age-related diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Antibody therapeutics, with their targeted and precision-based mechanisms, are well-suited for addressing the underlying causes of these diseases. As per the World Health Organization (WHO), one in six people will be 60 or older by 2030. The number of people 60 and older in the world will increase from 1 billion in 2020 to 1.4 billion in 2050. By 2050, there will be 2.1 billion people in the world who are 60 or older. It is anticipated that there will be 426 million persons 80 or older by 2050. This preference for targeted therapies aligns with the growing awareness of minimizing side effects in older populations. Increasing number of senior citizens has been a pivotal factor in driving the growth of the market.

Further, the pandemic highlighted vulnerabilities in global supply chains, affecting pharmaceutical product development and distribution, particularly antibody therapeutics. Disruptions in the supply chain, shortages of critical raw materials, and logistical challenges impacted the manufacturing and delivery of antibody drugs. Monoclonal antibodies were also deployed for prophylactic use in individuals at high risk of exposure to COVID-19, like those with underlying health conditions or individuals in close contact with infected individuals. The success of mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, shifted attention towards nucleic acid-based therapies. While there was a heightened focus on infectious disease research, including antibody therapeutics for COVID-19, other therapeutic areas experienced shifts in priorities and resource allocation. Thus, the COVID-19 pandemic had a moderate effect on the market.

However, the research and development of antibody therapeutics involves substantial costs, including preclinical studies, clinical trials, and manufacturing expenses. The high investment required can pose a barrier, especially for smaller biotech companies, hindering their ability to bring novel antibodies to market. The financial burden associated with antibody development may lead to a focus on well-established targets and therapeutic areas, potentially limiting exploration in areas with significant unmet medical needs. This reduced innovation and diversity in the development pipeline can hinder the discovery of breakthrough therapies. High development costs of antibody therapeutics are a significant challenge that hampers the growth of the market.

By Route of Administration Outlook

On the basis of route of administration, the market is divided into intravenous, subcutaneous, and others. In 2022, the intravenous segment dominated the market with maximum revenue share. Intravenous administration ensures rapid and complete bioavailability of antibody therapeutics. This route allows the drug to enter the bloodstream directly, avoiding barriers such as the gastrointestinal tract, which can impact absorption rates. Intravenous delivery allows for precise dosing and control over the rate of administration. Healthcare professionals can carefully regulate the infusion rate to achieve therapeutic levels in the bloodstream, optimizing the efficacy of antibody therapeutics. Intravenous administration provides an immediate onset of action for antibody therapeutics. This is crucial when rapid therapeutic effects are needed, such as in treating acute conditions or emergencies.

By Format Outlook

By format, the market is categorized into monoclonal antibody, polyclonal antibody therapy, bispecific antibody, antibody fragment, and others. The antibody fragment segment procured a promising growth rate in the market in 2022. Antibody fragments typically exhibit faster clearance from the circulatory system compared to full-length antibodies. This rapid clearance can be beneficial when a quick onset of action or a shorter half-life is desired, providing greater control over the timing and duration of the therapeutic effect. Antibody fragments are widely used in diagnostic imaging applications. Their smaller size allows for rapid clearance from non-target tissues, improving imaging contrast. Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) frequently use radiolabeled antibody fragments. Antibody fragments are explored for therapeutic applications in autoimmune diseases, where targeted and localized immunosuppression is desired.

By Source Outlook

By source, the market is segmented into human, humanized, chimeric, and others. In 2022, the human segment registered the maximum revenue share in the market. Human innovation and technological advancements, such as genetic engineering, monoclonal antibody production, and novel drug delivery systems, contribute to creating more effective and targeted antibody therapies. Human efforts in educating healthcare professionals, patients, and the public about the benefits and availability of antibody therapeutics contribute to their acceptance and utilization. Humans participate in clinical trials to test the efficacy and safety of antibody therapeutics. Their participation generates valuable data that inform the development process and regulatory approvals.

By End User Outlook

Based on end user, the market is fragmented into hospitals, long-term care facilities, and others. The long-term care facilities segment covered a considerable revenue share in the market in 2022. Long-term care facilities often cater to an aging population, which is more susceptible to conditions that may benefit from antibody therapeutics, including certain types of cancer, rheumatoid arthritis, and neurodegenerative disorders. The use of antibody therapeutics in long-term care facilities can reduce hospitalization rates. This is particularly important for residents who may have difficulty traveling to hospitals or are at higher risk of complications from hospital stays. Antibody therapeutics, particularly monoclonal antibodies, can prevent and manage infections. These treatments can support overall health maintenance in long-term care settings where people may be more susceptible to infections.

By Disease Areas Outlook

Based on disease areas, the market is classified into autoimmune & inflammatory diseases, oncology, hematology, infectious diseases, osteology, immunology, neurology, and others. The oncology segment procured a promising growth rate in the market in 2022. Antibody therapeutics are often combined with other cancer treatments, such as chemotherapy, targeted therapies, and radiation therapy. Combinatorial approaches aim to maximize treatment efficacy and address multiple aspects of cancer biology. Antibody therapeutics have proven effective in treating hematologic cancers, including various lymphomas and leukemias. Monoclonal antibodies, such as rituximab and alemtuzumab, target specific markers on cancer cells, leading to improved outcomes. Radioimmunotherapy involves antibodies labeled with radioactive isotopes to selectively deliver radiation to cancer cells. Ibritumomab, tiuxetan, and tositumomab are examples of radioimmunotherapy used in certain lymphomas.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. North America, particularly the United States, is home to a vibrant and well-established pharmaceutical research and development ecosystem. North America is a global hub for clinical trials, providing a robust infrastructure for conducting large-scale and diverse studies. The North American population has a relatively high prevalence of autoimmune diseases, like rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.

Strategies Deployed in Antibody Therapeutics market.

Dec-2023: AbbVie, Inc. came into partnership with BigHat Biosciences, a US-based biotechnology research company. Through this partnership, AbbVie, Inc. would explore and advance the development of cutting-edge therapeutic antibodies in the fields of oncology and neuroscience."

Dec-2023: AbbVie, Inc. took over Cerevel Therapeutics Hldg, biotech company in United States. Through this acquisition, AbbVie, Inc. would enhance its neuroscience portfolio.

Feb-2023: F. Hoffmann-La Roche Ltd came into partnership with Janssen Biotech Inc., a US-based pharmaceutical company. Through this partnership, F. Hoffmann-La Roche Ltd would enhance and develop companion diagnostics for targeted therapies. Additionally, this initiative strengthens the connection between diagnostics and treatments, fostering progress in precision healthcare.

Dec-2022: Merck KGaA came into partnership with Mersana Therapeutics, a biotech company in the United States. Through this partnership, Merck KGaA would develop innovative immunostimulatory antibody-drug conjugates.

Oct-2022: F. Hoffmann-La Roche Ltd came into partnership with Atea Pharmaceuticals, a US-based biotechnology research company. Through this partnership, F. Hoffmann-La Roche Ltd would create a prospective oral therapy for individuals with covid-19. Additionally, this therapy enables extensive production and promotes widespread patient availability.

Oct-2022: F. Hoffmann-La Roche Ltd introduced 'SARS-CoV-2 Rapid Antibody Test 2.0'. The SARS-CoV-2 Rapid Antibody Test 2.0 provides wider applicability than its initial design and now encompasses individuals who have been vaccinated.

Apr-2020: Johnson & Johnson came into partnership with Catalent, Inc., a US-based pharmaceutical manufacturing company. Through this partnership, Johnson & Johnson would enhance its manufacturing capability and lead vaccine candidates for COVID-19.

Mar-2019: Bristol Myers Squibb Company took over Celgene Corporation, a pharmaceutical company in the United States. Through this acquisition, Bristol Myers Squibb Company would establish a biopharmaceutical company.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration

• Intravenous
• Subcutaneous
• Others

By Format

• Monoclonal Antibody
• Polyclonal Antibody Therapy
• Bispecific Antibody
• Antibody fragment & Others

By Source

• Human
• Humanized
• Chimeric

By End User

• Hospitals
• Long-term care facilities
• Other

By Disease Areas

• Autoimmune & Inflammatory Diseases
• Neurology
• Osteology
• Hematology
• Oncology
• Infectious Diseases
• Immunology
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• F. Hoffmann-La Roche Ltd
• AbbVie, Inc.
• Johnson & Johnson (Johnson & Johnson Services, Inc.)
• Merck KGaA
• Bristol Myers Squibb Company
• AstraZeneca PLC
• Sanofi S.A.
• Novartis AG
• Biogen, Inc.
• Amgen, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Antibody Therapeutics Market, by Route of Administration
  • 1.4.2 Global Antibody Therapeutics Market, by Format
  • 1.4.3 Global Antibody Therapeutics Market, by Source
  • 1.4.4 Global Antibody Therapeutics Market, by End User
  • 1.4.5 Global Antibody Therapeutics Market, by Disease Areas
  • 1.4.6 Global Antibody Therapeutics Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
• 3.3 Porter Five Forces Analysis

Chapter 4. Strategies Deployed in Antibody Therapeutics market.

Chapter 5. Global Antibody Therapeutics Market by Route of Administration

• 5.1 Global Intravenous Market by Region
• 5.2 Global Subcutaneous Market by Region
• 5.3 Global Others Market by Region

Chapter 6. Global Antibody Therapeutics Market by Format

• 6.1 Global Monoclonal Antibody Market by Region
• 6.2 Global Polyclonal Antibody Therapy Market by Region
• 6.3 Global Bispecific Antibody Market by Region
• 6.4 Global Antibody fragment & Others Market by Region

Chapter 7. Global Antibody Therapeutics Market by Source

• 7.1 Global Human Market by Region
• 7.2 Global Humanized Market by Region
• 7.3 Global Chimeric Market by Region
• 7.4 Global Others Market by Region

Chapter 8. Global Antibody Therapeutics Market by End User

• 8.1 Global Hospitals Market by Region
• 8.2 Global Long-term care facilities Market by Region
• 8.3 Global Others Market by Region

Chapter 9. Global Antibody Therapeutics Market by Disease Areas

• 9.1 Global Autoimmune & Inflammatory Diseases Market by Region
• 9.2 Global Neurology Market by Region
• 9.3 Global Osteology Market by Region
• 9.4 Global Hematology Market by Region
• 9.5 Global Oncology Market by Region
• 9.6 Global Infectious Diseases Market by Region
• 9.7 Global Immunology Market by Region
• 9.8 Global Others Market by Region

Chapter 10. Global Antibody Therapeutics Market by Region

• 10.1 North America Antibody Therapeutics Market
  • 10.1.1 North America Antibody Therapeutics Market by Route of Administration
    • 10.1.1.1 North America Intravenous Market by Country
    • 10.1.1.2 North America Subcutaneous Market by Country
    • 10.1.1.3 North America Others Market by Country
  • 10.1.2 North America Antibody Therapeutics Market by Format
    • 10.1.2.1 North America Monoclonal Antibody Market by Country
    • 10.1.2.2 North America Polyclonal Antibody Therapy Market by Country
    • 10.1.2.3 North America Bispecific Antibody Market by Country
    • 10.1.2.4 North America Antibody fragment & Others Market by Country
  • 10.1.3 North America Antibody Therapeutics Market by Source
    • 10.1.3.1 North America Human Market by Country
    • 10.1.3.2 North America Humanized Market by Country
    • 10.1.3.3 North America Chimeric Market by Country
    • 10.1.3.4 North America Others Market by Country
  • 10.1.4 North America Antibody Therapeutics Market by End User
    • 10.1.4.1 North America Hospitals Market by Country
    • 10.1.4.2 North America Long-term care facilities Market by Country
    • 10.1.4.3 North America Others Market by Country
  • 10.1.5 North America Antibody Therapeutics Market by Disease Areas
    • 10.1.5.1 North America Autoimmune & Inflammatory Diseases Market by Country
    • 10.1.5.2 North America Neurology Market by Country
    • 10.1.5.3 North America Osteology Market by Country
    • 10.1.5.4 North America Hematology Market by Country
    • 10.1.5.5 North America Oncology Market by Country
    • 10.1.5.6 North America Infectious Diseases Market by Country
    • 10.1.5.7 North America Immunology Market by Country
    • 10.1.5.8 North America Others Market by Country
  • 10.1.6 North America Antibody Therapeutics Market by Country
    • 10.1.6.1 US Antibody Therapeutics Market
      • 10.1.6.1.1 US Antibody Therapeutics Market by Route of Administration
      • 10.1.6.1.2 US Antibody Therapeutics Market by Format
      • 10.1.6.1.3 US Antibody Therapeutics Market by Source
      • 10.1.6.1.4 US Antibody Therapeutics Market by End User
      • 10.1.6.1.5 US Antibody Therapeutics Market by Disease Areas
    • 10.1.6.2 Canada Antibody Therapeutics Market
      • 10.1.6.2.1 Canada Antibody Therapeutics Market by Route of Administration
      • 10.1.6.2.2 Canada Antibody Therapeutics Market by Format
      • 10.1.6.2.3 Canada Antibody Therapeutics Market by Source
      • 10.1.6.2.4 Canada Antibody Therapeutics Market by End User
      • 10.1.6.2.5 Canada Antibody Therapeutics Market by Disease Areas
    • 10.1.6.3 Mexico Antibody Therapeutics Market
      • 10.1.6.3.1 Mexico Antibody Therapeutics Market by Route of Administration
      • 10.1.6.3.2 Mexico Antibody Therapeutics Market by Format
      • 10.1.6.3.3 Mexico Antibody Therapeutics Market by Source
      • 10.1.6.3.4 Mexico Antibody Therapeutics Market by End User
      • 10.1.6.3.5 Mexico Antibody Therapeutics Market by Disease Areas
    • 10.1.6.4 Rest of North America Antibody Therapeutics Market
      • 10.1.6.4.1 Rest of North America Antibody Therapeutics Market by Route of Administration
      • 10.1.6.4.2 Rest of North America Antibody Therapeutics Market by Format
      • 10.1.6.4.3 Rest of North America Antibody Therapeutics Market by Source
      • 10.1.6.4.4 Rest of North America Antibody Therapeutics Market by End User
      • 10.1.6.4.5 Rest of North America Antibody Therapeutics Market by Disease Areas
• 10.2 Europe Antibody Therapeutics Market
  • 10.2.1 Europe Antibody Therapeutics Market by Route of Administration
    • 10.2.1.1 Europe Intravenous Market by Country
    • 10.2.1.2 Europe Subcutaneous Market by Country
    • 10.2.1.3 Europe Others Market by Country
  • 10.2.2 Europe Antibody Therapeutics Market by Format
    • 10.2.2.1 Europe Monoclonal Antibody Market by Country
    • 10.2.2.2 Europe Polyclonal Antibody Therapy Market by Country
    • 10.2.2.3 Europe Bispecific Antibody Market by Country
    • 10.2.2.4 Europe Antibody fragment & Others Market by Country
  • 10.2.3 Europe Antibody Therapeutics Market by Source
    • 10.2.3.1 Europe Human Market by Country
    • 10.2.3.2 Europe Humanized Market by Country
    • 10.2.3.3 Europe Chimeric Market by Country
    • 10.2.3.4 Europe Others Market by Country
  • 10.2.4 Europe Antibody Therapeutics Market by End User
    • 10.2.4.1 Europe Hospitals Market by Country
    • 10.2.4.2 Europe Long-term care facilities Market by Country
    • 10.2.4.3 Europe Others Market by Country
  • 10.2.5 Europe Antibody Therapeutics Market by Disease Areas
    • 10.2.5.1 Europe Autoimmune & Inflammatory Diseases Market by Country
    • 10.2.5.2 Europe Neurology Market by Country
    • 10.2.5.3 Europe Osteology Market by Country
    • 10.2.5.4 Europe Hematology Market by Country
    • 10.2.5.5 Europe Oncology Market by Country
    • 10.2.5.6 Europe Infectious Diseases Market by Country
    • 10.2.5.7 Europe Immunology Market by Country
    • 10.2.5.8 Europe Others Market by Country
  • 10.2.6 Europe Antibody Therapeutics Market by Country
    • 10.2.6.1 Germany Antibody Therapeutics Market
      • 10.2.6.1.1 Germany Antibody Therapeutics Market by Route of Administration
      • 10.2.6.1.2 Germany Antibody Therapeutics Market by Format
      • 10.2.6.1.3 Germany Antibody Therapeutics Market by Source
      • 10.2.6.1.4 Germany Antibody Therapeutics Market by End User
      • 10.2.6.1.5 Germany Antibody Therapeutics Market by Disease Areas
    • 10.2.6.2 UK Antibody Therapeutics Market
      • 10.2.6.2.1 UK Antibody Therapeutics Market by Route of Administration
      • 10.2.6.2.2 UK Antibody Therapeutics Market by Format
      • 10.2.6.2.3 UK Antibody Therapeutics Market by Source
      • 10.2.6.2.4 UK Antibody Therapeutics Market by End User
      • 10.2.6.2.5 UK Antibody Therapeutics Market by Disease Areas
    • 10.2.6.3 France Antibody Therapeutics Market
      • 10.2.6.3.1 France Antibody Therapeutics Market by Route of Administration
      • 10.2.6.3.2 France Antibody Therapeutics Market by Format
      • 10.2.6.3.3 France Antibody Therapeutics Market by Source
      • 10.2.6.3.4 France Antibody Therapeutics Market by End User
      • 10.2.6.3.5 France Antibody Therapeutics Market by Disease Areas
    • 10.2.6.4 Russia Antibody Therapeutics Market
      • 10.2.6.4.1 Russia Antibody Therapeutics Market by Route of Administration
      • 10.2.6.4.2 Russia Antibody Therapeutics Market by Format
      • 10.2.6.4.3 Russia Antibody Therapeutics Market by Source
      • 10.2.6.4.4 Russia Antibody Therapeutics Market by End User
      • 10.2.6.4.5 Russia Antibody Therapeutics Market by Disease Areas
    • 10.2.6.5 Spain Antibody Therapeutics Market
      • 10.2.6.5.1 Spain Antibody Therapeutics Market by Route of Administration
      • 10.2.6.5.2 Spain Antibody Therapeutics Market by Format
      • 10.2.6.5.3 Spain Antibody Therapeutics Market by Source
      • 10.2.6.5.4 Spain Antibody Therapeutics Market by End User
      • 10.2.6.5.5 Spain Antibody Therapeutics Market by Disease Areas
    • 10.2.6.6 Italy Antibody Therapeutics Market
      • 10.2.6.6.1 Italy Antibody Therapeutics Market by Route of Administration
      • 10.2.6.6.2 Italy Antibody Therapeutics Market by Format
      • 10.2.6.6.3 Italy Antibody Therapeutics Market by Source
      • 10.2.6.6.4 Italy Antibody Therapeutics Market by End User
      • 10.2.6.6.5 Italy Antibody Therapeutics Market by Disease Areas
    • 10.2.6.7 Rest of Europe Antibody Therapeutics Market
      • 10.2.6.7.1 Rest of Europe Antibody Therapeutics Market by Route of Administration
      • 10.2.6.7.2 Rest of Europe Antibody Therapeutics Market by Format
      • 10.2.6.7.3 Rest of Europe Antibody Therapeutics Market by Source
      • 10.2.6.7.4 Rest of Europe Antibody Therapeutics Market by End User
      • 10.2.6.7.5 Rest of Europe Antibody Therapeutics Market by Disease Areas
• 10.3 Asia Pacific Antibody Therapeutics Market
  • 10.3.1 Asia Pacific Antibody Therapeutics Market by Route of Administration
    • 10.3.1.1 Asia Pacific Intravenous Market by Country
    • 10.3.1.2 Asia Pacific Subcutaneous Market by Country
    • 10.3.1.3 Asia Pacific Others Market by Country
  • 10.3.2 Asia Pacific Antibody Therapeutics Market by Format
    • 10.3.2.1 Asia Pacific Monoclonal Antibody Market by Country
    • 10.3.2.2 Asia Pacific Polyclonal Antibody Therapy Market by Country
    • 10.3.2.3 Asia Pacific Bispecific Antibody Market by Country
    • 10.3.2.4 Asia Pacific Antibody fragment & Others Market by Country
  • 10.3.3 Asia Pacific Antibody Therapeutics Market by Source
    • 10.3.3.1 Asia Pacific Human Market by Country
    • 10.3.3.2 Asia Pacific Humanized Market by Country
    • 10.3.3.3 Asia Pacific Chimeric Market by Country
    • 10.3.3.4 Asia Pacific Others Market by Country
  • 10.3.4 Asia Pacific Antibody Therapeutics Market by End User
    • 10.3.4.1 Asia Pacific Hospitals Market by Country
    • 10.3.4.2 Asia Pacific Long-term care facilities Market by Country
    • 10.3.4.3 Asia Pacific Others Market by Country
  • 10.3.5 Asia Pacific Antibody Therapeutics Market by Disease Areas
    • 10.3.5.1 Asia Pacific Autoimmune & Inflammatory Diseases Market by Country
    • 10.3.5.2 Asia Pacific Neurology Market by Country
    • 10.3.5.3 Asia Pacific Osteology Market by Country
    • 10.3.5.4 Asia Pacific Hematology Market by Country
    • 10.3.5.5 Asia Pacific Oncology Market by Country
    • 10.3.5.6 Asia Pacific Infectious Diseases Market by Country
    • 10.3.5.7 Asia Pacific Immunology Market by Country
    • 10.3.5.8 Asia Pacific Others Market by Country
  • 10.3.6 Asia Pacific Antibody Therapeutics Market by Country
    • 10.3.6.1 China Antibody Therapeutics Market
      • 10.3.6.1.1 China Antibody Therapeutics Market by Route of Administration
      • 10.3.6.1.2 China Antibody Therapeutics Market by Format
      • 10.3.6.1.3 China Antibody Therapeutics Market by Source
      • 10.3.6.1.4 China Antibody Therapeutics Market by End User
      • 10.3.6.1.5 China Antibody Therapeutics Market by Disease Areas
    • 10.3.6.2 Japan Antibody Therapeutics Market
      • 10.3.6.2.1 Japan Antibody Therapeutics Market by Route of Administration
      • 10.3.6.2.2 Japan Antibody Therapeutics Market by Format
      • 10.3.6.2.3 Japan Antibody Therapeutics Market by Source
      • 10.3.6.2.4 Japan Antibody Therapeutics Market by End User
      • 10.3.6.2.5 Japan Antibody Therapeutics Market by Disease Areas
    • 10.3.6.3 India Antibody Therapeutics Market
      • 10.3.6.3.1 India Antibody Therapeutics Market by Route of Administration
      • 10.3.6.3.2 India Antibody Therapeutics Market by Format
      • 10.3.6.3.3 India Antibody Therapeutics Market by Source
      • 10.3.6.3.4 India Antibody Therapeutics Market by End User
      • 10.3.6.3.5 India Antibody Therapeutics Market by Disease Areas
    • 10.3.6.4 South Korea Antibody Therapeutics Market
      • 10.3.6.4.1 South Korea Antibody Therapeutics Market by Route of Administration
      • 10.3.6.4.2 South Korea Antibody Therapeutics Market by Format
      • 10.3.6.4.3 South Korea Antibody Therapeutics Market by Source
      • 10.3.6.4.4 South Korea Antibody Therapeutics Market by End User
      • 10.3.6.4.5 South Korea Antibody Therapeutics Market by Disease Areas
    • 10.3.6.5 Singapore Antibody Therapeutics Market
      • 10.3.6.5.1 Singapore Antibody Therapeutics Market by Route of Administration
      • 10.3.6.5.2 Singapore Antibody Therapeutics Market by Format
      • 10.3.6.5.3 Singapore Antibody Therapeutics Market by Source
      • 10.3.6.5.4 Singapore Antibody Therapeutics Market by End User
      • 10.3.6.5.5 Singapore Antibody Therapeutics Market by Disease Areas
    • 10.3.6.6 Malaysia Antibody Therapeutics Market
      • 10.3.6.6.1 Malaysia Antibody Therapeutics Market by Route of Administration
      • 10.3.6.6.2 Malaysia Antibody Therapeutics Market by Format
      • 10.3.6.6.3 Malaysia Antibody Therapeutics Market by Source
      • 10.3.6.6.4 Malaysia Antibody Therapeutics Market by End User
      • 10.3.6.6.5 Malaysia Antibody Therapeutics Market by Disease Areas
    • 10.3.6.7 Rest of Asia Pacific Antibody Therapeutics Market
      • 10.3.6.7.1 Rest of Asia Pacific Antibody Therapeutics Market by Route of Administration
      • 10.3.6.7.2 Rest of Asia Pacific Antibody Therapeutics Market by Format
      • 10.3.6.7.3 Rest of Asia Pacific Antibody Therapeutics Market by Source
      • 10.3.6.7.4 Rest of Asia Pacific Antibody Therapeutics Market by End User
      • 10.3.6.7.5 Rest of Asia Pacific Antibody Therapeutics Market by Disease Areas
• 10.4 LAMEA Antibody Therapeutics Market
  • 10.4.1 LAMEA Antibody Therapeutics Market by Route of Administration
    • 10.4.1.1 LAMEA Intravenous Market by Country
    • 10.4.1.2 LAMEA Subcutaneous Market by Country
    • 10.4.1.3 LAMEA Others Market by Country
  • 10.4.2 LAMEA Antibody Therapeutics Market by Format
    • 10.4.2.1 LAMEA Monoclonal Antibody Market by Country
    • 10.4.2.2 LAMEA Polyclonal Antibody Therapy Market by Country
    • 10.4.2.3 LAMEA Bispecific Antibody Market by Country
    • 10.4.2.4 LAMEA Antibody fragment & Others Market by Country
  • 10.4.3 LAMEA Antibody Therapeutics Market by Source
    • 10.4.3.1 LAMEA Human Market by Country
    • 10.4.3.2 LAMEA Humanized Market by Country
    • 10.4.3.3 LAMEA Chimeric Market by Country
    • 10.4.3.4 LAMEA Others Market by Country
  • 10.4.4 LAMEA Antibody Therapeutics Market by End User
    • 10.4.4.1 LAMEA Hospitals Market by Country
    • 10.4.4.2 LAMEA Long-term care facilities Market by Country
    • 10.4.4.3 LAMEA Others Market by Country
  • 10.4.5 LAMEA Antibody Therapeutics Market by Disease Areas
    • 10.4.5.1 LAMEA Autoimmune & Inflammatory Diseases Market by Country
    • 10.4.5.2 LAMEA Neurology Market by Country
    • 10.4.5.3 LAMEA Osteology Market by Country
    • 10.4.5.4 LAMEA Hematology Market by Country
    • 10.4.5.5 LAMEA Oncology Market by Country
    • 10.4.5.6 LAMEA Infectious Diseases Market by Country
    • 10.4.5.7 LAMEA Immunology Market by Country
    • 10.4.5.8 LAMEA Others Market by Country
  • 10.4.6 LAMEA Antibody Therapeutics Market by Country
    • 10.4.6.1 Brazil Antibody Therapeutics Market
      • 10.4.6.1.1 Brazil Antibody Therapeutics Market by Route of Administration
      • 10.4.6.1.2 Brazil Antibody Therapeutics Market by Format
      • 10.4.6.1.3 Brazil Antibody Therapeutics Market by Source
      • 10.4.6.1.4 Brazil Antibody Therapeutics Market by End User
      • 10.4.6.1.5 Brazil Antibody Therapeutics Market by Disease Areas
    • 10.4.6.2 Argentina Antibody Therapeutics Market
      • 10.4.6.2.1 Argentina Antibody Therapeutics Market by Route of Administration
      • 10.4.6.2.2 Argentina Antibody Therapeutics Market by Format
      • 10.4.6.2.3 Argentina Antibody Therapeutics Market by Source
      • 10.4.6.2.4 Argentina Antibody Therapeutics Market by End User
      • 10.4.6.2.5 Argentina Antibody Therapeutics Market by Disease Areas
    • 10.4.6.3 UAE Antibody Therapeutics Market
      • 10.4.6.3.1 UAE Antibody Therapeutics Market by Route of Administration
      • 10.4.6.3.2 UAE Antibody Therapeutics Market by Format
      • 10.4.6.3.3 UAE Antibody Therapeutics Market by Source
      • 10.4.6.3.4 UAE Antibody Therapeutics Market by End User
      • 10.4.6.3.5 UAE Antibody Therapeutics Market by Disease Areas
    • 10.4.6.4 Saudi Arabia Antibody Therapeutics Market
      • 10.4.6.4.1 Saudi Arabia Antibody Therapeutics Market by Route of Administration
      • 10.4.6.4.2 Saudi Arabia Antibody Therapeutics Market by Format
      • 10.4.6.4.3 Saudi Arabia Antibody Therapeutics Market by Source
      • 10.4.6.4.4 Saudi Arabia Antibody Therapeutics Market by End User
      • 10.4.6.4.5 Saudi Arabia Antibody Therapeutics Market by Disease Areas
    • 10.4.6.5 South Africa Antibody Therapeutics Market
      • 10.4.6.5.1 South Africa Antibody Therapeutics Market by Route of Administration
      • 10.4.6.5.2 South Africa Antibody Therapeutics Market by Format
      • 10.4.6.5.3 South Africa Antibody Therapeutics Market by Source
      • 10.4.6.5.4 South Africa Antibody Therapeutics Market by End User
      • 10.4.6.5.5 South Africa Antibody Therapeutics Market by Disease Areas
    • 10.4.6.6 Nigeria Antibody Therapeutics Market
      • 10.4.6.6.1 Nigeria Antibody Therapeutics Market by Route of Administration
      • 10.4.6.6.2 Nigeria Antibody Therapeutics Market by Format
      • 10.4.6.6.3 Nigeria Antibody Therapeutics Market by Source
      • 10.4.6.6.4 Nigeria Antibody Therapeutics Market by End User
      • 10.4.6.6.5 Nigeria Antibody Therapeutics Market by Disease Areas
    • 10.4.6.7 Rest of LAMEA Antibody Therapeutics Market
      • 10.4.6.7.1 Rest of LAMEA Antibody Therapeutics Market by Route of Administration
      • 10.4.6.7.2 Rest of LAMEA Antibody Therapeutics Market by Format
      • 10.4.6.7.3 Rest of LAMEA Antibody Therapeutics Market by Source
      • 10.4.6.7.4 Rest of LAMEA Antibody Therapeutics Market by End User
      • 10.4.6.7.5 Rest of LAMEA Antibody Therapeutics Market by Disease Areas

Chapter 11. Company Profiles

• 11.1 F. Hoffmann-La Roche Ltd.
  • 11.1.1 Company Overview
  • 11.1.2 Financial Analysis
  • 11.1.3 Segmental and Regional Analysis
  • 11.1.4 Research & Development Expense
  • 11.1.5 Recent strategies and developments:
    • 11.1.5.1 Partnerships, Collaborations, and Agreements:
    • 11.1.5.2 Product Launches and Product Expansions:
  • 11.1.6 SWOT Analysis
• 11.2 AbbVie, Inc.
  • 11.2.1 Company Overview
  • 11.2.2 Financial Analysis
  • 11.2.3 Regional Analysis
  • 11.2.4 Research & Development Expense
  • 11.2.5 Recent strategies and developments:
    • 11.2.5.1 Partnerships, Collaborations, and Agreements:
    • 11.2.5.2 Acquisition and Mergers:
  • 11.2.6 SWOT Analysis
• 11.3 Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • 11.3.1 Company Overview
  • 11.3.2 Financial Analysis
  • 11.3.3 Segmental &Regional Analysis
  • 11.3.4 Research & Development Expenses
  • 11.3.5 Recent strategies and developments:
    • 11.3.5.1 Partnerships, Collaborations, and Agreements:
  • 11.3.6 SWOT Analysis
• 11.4 Merck KGaA
  • 11.4.1 Company Overview
  • 11.4.2 Financial Analysis
  • 11.4.3 Segmental and Regional Analysis
  • 11.4.4 Research & Development Expense
  • 11.4.5 Recent strategies and developments:
    • 11.4.5.1 Partnerships, Collaborations, and Agreements:
  • 11.4.6 SWOT Analysis
• 11.5 Bristol Myers Squibb Company
  • 11.5.1 Company Overview
  • 11.5.2 Financial Analysis
  • 11.5.3 Regional Analysis
  • 11.5.4 Research & Development Expenses
  • 11.5.5 Recent strategies and developments:
    • 11.5.5.1 Acquisition and Mergers:
  • 11.5.6 SWOT Analysis
• 11.6 AstraZeneca PLC
  • 11.6.1 Company Overview
  • 11.6.2 Financial Analysis
  • 11.6.3 Regional Analysis
  • 11.6.4 Research & Development Expenses
  • 11.6.5 SWOT Analysis
• 11.7 Sanofi S.A.
  • 11.7.1 Company Overview
  • 11.7.2 Financial Analysis
  • 11.7.3 Segmental and Regional Analysis
  • 11.7.4 Research & Development Expense
  • 11.7.5 SWOT Analysis
• 11.8 Novartis AG
  • 11.8.1 Company Overview
  • 11.8.2 Financial Analysis
  • 11.8.3 Segmental and Regional Analysis
  • 11.8.4 Research & Development Expense
  • 11.8.5 SWOT Analysis
• 11.9 Biogen, Inc.
  • 11.9.1 Company Overview
  • 11.9.2 Financial Analysis
  • 11.9.3 Regional Analysis
  • 11.9.4 Research & Development Expense
  • 11.9.5 SWOT Analysis
• 11.10. Amgen, Inc.
  • 11.10.1 Company Overview
  • 11.10.2 Financial Analysis
  • 11.10.3 Regional Analysis
  • 11.10.4 Research & Development Expenses
  • 11.10.5 SWOT Analysis

Chapter 12. Winning Imperative for Antibody Therapeutics Market